Palvella Therapeutics Q3 2026 Net Loss More Than Doubles to $24.64 Million

Bitget2026/11/05 12:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Palvella Therapeutics’ third-quarter 2026 net loss more than doubled to $24.64 million from a year earlier.
General and administrative expenses more than tripled to $11.9 million, while research and development spending rose 66% to $10.82 million.
Cash, cash equivalents and short-term investments totaled $236.7 million at September 30, 2026.
The FDA accepted QTORIN rapamycin’s application for microcystic lymphatic malformations, granting priority review with a February 28, 2027 target action date.
A standalone U.S. commercial launch is planned for the first half of 2027, subject to FDA approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050730PRIMZONEFULLFEED9870892) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Palvella Therapeutics Q3 2026 Net Loss More Than Doubles to $24.64 Million

You may also like

Crypto prices